NASDAQ: MISTMilestone Pharmaceuticals Inc Stock
$1.76+0.03 (+1.73%)
Updated Apr 15, 2024
MIST Price
$1.76
Fair Value Price
-$0.90
Market Cap
$93.28M
52 Week Low
$1.33
52 Week High
$4.49
P/E
-1.26x
P/B
5.56x
P/S
71.74x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.00M
Earnings
-$59.69M
Gross Margin
100%
Operating Margin
-5,713.1%
Profit Margin
-5,968.5%
Debt to Equity
3.49
Operating Cash Flow
-$46M
Beta
0.21
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
MIST Overview
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MIST scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MIST ($1.76) is overvalued by 295.73% relative to our estimate of its Fair Value price of -$0.90 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MIST ($1.76) is not significantly undervalued (295.73%) relative to our estimate of its Fair Value price of -$0.90 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MIST is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MIST due diligence checks available for Premium users.
Be the first to know about important MIST news, forecast changes, insider trades & much more!
MIST News
Valuation
MIST fair value
Fair Value of MIST stock based on Discounted Cash Flow (DCF)
Price
$1.76
Fair Value
-$0.90
Undervalued by
296.29%
MIST ($1.76) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MIST ($1.76) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MIST is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MIST price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.26x
Industry
14.94x
Market
41.94x
MIST price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.56x
Industry
5.88x
MIST is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MIST's financial health
Profit margin
Revenue
$0.0
Net Income
-$13.6M
Profit Margin
0%
MIST's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MIST's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$75.2M
Liabilities
$58.5M
Debt to equity
3.49
MIST's short-term assets ($73.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MIST's short-term assets ($73.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MIST's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MIST's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.8M
Investing
$13.7M
Financing
$1.0k
MIST's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MIST vs Biotech Stocks
Milestone Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.